Von Eschenbach Promotes Behind-The-Counter Drug Class
This article was originally published in The Tan Sheet
Executive Summary
FDA and industry should immediately begin pursuing the development of a regulatory process for a behind-the-counter class of drugs, FDA Commissioner Andrew C. von Eschenbach, M.D., told OTC industry executives March 16
You may also be interested in...
Von Eschenbach Resigning In January With BTC Debate In His Legacy
FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed
Von Eschenbach Resigning In January With BTC Debate In His Legacy
FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed
Von Eschenbach Resigning In January With BTC Debate In His Legacy
FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed